50 Tice Blvd, Suite 315
Tel: (201) 326-5300
241 articles with Eagle Pharmaceuticals
Eagle Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
Eagle Pharmaceuticals, Inc. announced financial results for the three months ended March 31, 2020.
Eagle Pharmaceuticals Advances Novel and Proprietary Formulation of Fulvestrant Product Candidate EA-114; Company to Request Additional Meeting with U.S. Food and Drug Administration (“FDA”)
Eagle Pharmaceuticals, Inc. provided an update on its pilot clinical study to assess the unique characteristics of its fulvestrant product candidate, EA-114, which has the potential to enhance estrogen receptor inhibition and improve patient outcomes.
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 first quarter financial results on Monday, May 11, 2020, before the market opens.
Shares of Eagle Pharmaceuticals and Teva Pharmaceuticals are climbing following a favorable ruling in U.S. District Court that protects the patent for cancer drug Bendeka from generic competition through 2031.
Court Issues Favorable Patent Litigation Decision for Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. for BENDEKA (bendamustine hydrochloride injection)
Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. announced that on April 27, 2020, the U.S. District Court for the District of Delaware has issued a patent decision in favor of Eagle and Teva for BENDEKA®, a liquid, low-volume and short-time 10-minute infusion formulation of bendamustine hydrochloride..
Eagle Pharmaceuticals Announces Laboratory Test Results Demonstrating In Vitro Antiviral Activity of RYANODEX® (dantrolene sodium) Against Coronavirus SARS-CoV-2
IND Submitted to FDA for Planned Clinical Study at Hackensack University Medical Center to Evaluate RYANODEX for Treatment of COVID-19 Patients
In a controlled laboratory test, Eagle Pharmaceuticals’ malignant hyperthermia treatment Ryanodex (dantrolene sodium) inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation
Eagle Pharmaceuticals, Inc. announced that its marketing partner SymBio Pharmaceuticals Limited has completed patient enrollment in a clinical trial for TREAKISYM rapid infusion, a liquid bendamustine injection with a 10-minute administration time, in Japan.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve months ended December 31, 2019.
Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020
Eagle Pharmaceuticals, Inc. announced that the Company will release its 2019 fourth quarter and full year financial results on Monday, March 2, 2020, before the market opens.
The FDA gave tentative approval for the drug in 2018, but the holdup was over patent issues.
Feb. 10, 2020 14:54 UTC Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY ™ (Pemetrexed for Injection) -- Eagle has exclusive rights to commercialize product for four months beginning February 1, 2022 -- WOODCLIFF LAKE, N.J.--( BUSINESS WIRE )-- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has received final approval from the U.S. Food and Drug Administration (“FDA”) for its novel product, PEMFEXY™ (pemetrexed for
With the J.P. Morgan Healthcare Conference in full swing, companies did not waste time in announcing deals and providing updates to their pipelines. BioSpace takes a look at some of the announcements made on day one of the annual conference in the Bay Area.
Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Disease in Collaboration With University of Pennsylvania
Eagle Pharmaceuticals, Inc. announced that Eagle and the University of Pennsylvania have agreed on terms of a new exclusive worldwide license agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease, including an agreement to fund additional research and provisions regarding commercialization of products developed under the license.
Eagle Pharmaceuticals, Inc. announced that the Company has resubmitted its New Drug Application for RYANODEX® for the treatment of exertional heat stroke, in addition to body cooling, to the U.S. Food and Drug Administration.
Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer
Collaboration leverages combined capabilities of Tyme Technologies and Eagle Pharmaceuticals to maximize potential of oral SM-88 by advancing pivotal trials and commercialization.
Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury
Eagle Pharmaceuticals, Inc. announced a new research agreement with NorthShore University HealthSystem in Evanston, IL, focused on studying Eagle’s RYANODEX® for traumatic brain injury in animal models.
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference